CBL and glioma: Synergistic activity with TRAIL or temozolomide was assessed in human U87 and D54 glioma cells using SRB assays and Chou-Talalay analysis.<h4>Results</h4>NO-Cbl showed broad antitumor activity <i>in vitro</i>, with central nervous system tumor cell lines displaying intermediate sensitivity (mean ID50 = 17.6 μM).